PMID: 9663360Jul 15, 1998Paper

Domperidone in the management of symptoms of diabetic gastroparesis: efficacy, tolerability, and quality-of-life outcomes in a multicenter controlled trial. DOM-USA-5 Study Group

Clinical Therapeutics
D SilversA Joslyn

Abstract

The purpose of this clinical study was to determine the efficacy, tolerability, and impact on quality of life of domperidone--a specific peripherally acting dopamine antagonist--in the management of symptoms of gastroparesis, a common and potentially debilitating condition in patients with diabetes mellitus. In the first phase of this multicenter, two-phase withdrawal study, 287 diabetic patients with symptoms of gastroparesis of at least 6 months' duration received domperidone 20 mg QID in a single-masked fashion for 4 weeks. Efficacy was evaluated using a four-point rating scale (0 = none, 1 = mild, 2 = moderate, 3 = severe) for each of the following symptoms: nausea, abdominal distention/bloating, early satiety, vomiting, and abdominal pain. At the end of the first phase, patients with sufficient improvement in their total symptom score (a score < or = 6 and a decrease in score of > or = 5 units from the baseline [selection] visit) were eligible for the 4-week, randomized, placebo-controlled, double-masked withdrawal phase of the study. The impact of domperidone on quality of life was determined using the Medical Outcomes Study Short Form-36 (SF-36). Of 269 patients with data from the single-masked phase, 208 (77%) qualified...Continue Reading

References

Jul 1, 1992·Digestive Diseases and Sciences·S McHughN E Diamant
Jan 1, 1991·European Journal of Nuclear Medicine·M HorowitzD J Shearman
Jan 1, 1985·Digestive Diseases and Sciences·M HorowitzD J Shearman
Dec 15, 1966·The New England Journal of Medicine·L A Katz, H M Spiro
Jan 1, 1983·Annals of Internal Medicine·R Albibi, R W McCallum
Mar 1, 1983·Annals of Internal Medicine·M Feldman, L R Schiller
May 20, 1995·BMJ : British Medical Journal·M J DaviesW P Goddard
Aug 1, 1993·Digestive Diseases and Sciences·R D RothsteinJ C Reynolds
Dec 17, 1997·Movement Disorders : Official Journal of the Movement Disorder Society·I SoykanR W McCallum
Mar 24, 2000·Journal of Clinical Gastroenterology·K Hornbuckle, J L Barnett
Jul 27, 2001·Current Treatment Options in Gastroenterology·Richard W. McCallum, Sabu J. George

❮ Previous
Next ❯

Citations

Jun 27, 2013·Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract·Allen Lee
Mar 11, 2004·Current Treatment Options in Gastroenterology·Daniel C. Buckles, Richard W. McCallum
Nov 30, 2000·Current Treatment Options in Gastroenterology·R W McCallum, R L Brown
Nov 30, 2000·Current Treatment Options in Gastroenterology·E M Quigley
Jul 16, 2003·Gastroenterology Clinics of North America·D Scott SmithChristopher D Ferris
Jul 25, 2000·Alimentary Pharmacology & Therapeutics·K L JonesM Horowitz
Apr 23, 2002·Alimentary Pharmacology & Therapeutics·A FranzeseS Cucchiara
Jul 30, 2002·Alimentary Pharmacology & Therapeutics·B BradenB Lembcke
Feb 23, 2007·The New England Journal of Medicine·Michael Camilleri
May 7, 2004·Journal of Clinical Gastroenterology·Rohtashav Dhir, Joel E Richter
Dec 23, 2009·World Journal of Gastroenterology : WJG·Klaus BielefeldtSusan L Zickmund
Mar 5, 2011·Saudi Journal of Gastroenterology : Official Journal of the Saudi Gastroenterology Association·Badr M Aljarallah
Jul 22, 1999·American Journal of Surgery·J S Thompson, E M Quigley
Dec 11, 2013·Acupuncture in Medicine : Journal of the British Medical Acupuncture Society·Netanella Danielli MillerRam Dickman
May 17, 2001·Current Gastroenterology Reports·S Khan, C Di Lorenzo
Sep 26, 2014·Saudi Journal of Gastroenterology : Official Journal of the Saudi Gastroenterology Association·Mahmoud H MosliMajid Al-Madi
Aug 30, 2014·Current Treatment Options in Gastroenterology·Benjamin SteinBrian E Lacy
Jul 21, 2015·Expert Opinion on Pharmacotherapy·Mark MalamoodRon Schey
Mar 8, 2008·Clinical Radiology·A A LevinI Laufer
Mar 24, 2006·Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society·T L AbellA I Vinik
Mar 16, 2001·Expert Opinion on Pharmacotherapy·E M Quigley
Oct 24, 2013·Expert Opinion on Drug Safety·Sheila A Doggrell, Jules C Hancox
Oct 27, 2004·Expert Opinion on Pharmacotherapy·Y VandenplasS Salvatore
Dec 5, 2014·Saudi Pharmaceutical Journal : SPJ : the Official Publication of the Saudi Pharmaceutical Society·Amjad KhanAkhlaq Mohammad
Oct 9, 2002·Oncology Nursing Forum·Karen L SchumacherChristine Miaskowski
Feb 4, 2016·Expert Review of Gastroenterology & Hepatology·James LangworthyRon Schey
Oct 24, 2007·Gastroenterology Clinics of North America·Michael Camilleri
Apr 26, 2016·Journal of Digestive Diseases·Shishira BharadwajAndrew Ukleja
Feb 11, 2015·Gastroenterology Clinics of North America·Andres Acosta, Michael Camilleri
Apr 4, 2003·AWHONN Lifelines·Amanda Henderson
Oct 8, 2016·Digestive Diseases and Sciences·Mohammad BashashatiRichard W McCallum
Aug 17, 2004·The Medical Clinics of North America·A I Vinik, Anahit Mehrabyan
May 10, 2007·The American Journal of Gastroenterology·Savio C ReddymasuRichard W McCallum
Feb 20, 2010·Journal of Diabetes Science and Technology·Lawrence A Szarka, Michael Camilleri
Feb 20, 2003·The American Journal of Gastroenterology·Nicholas J Talley
Mar 29, 2002·Diabetic Medicine : a Journal of the British Diabetic Association·M HorowitzM Samsom
Nov 8, 2017·Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society·J Heckert, H P Parkman
May 16, 2012·Journal of Pediatric Gastroenterology and Nutrition·Roberto GomezCarlo Di Lorenzo
May 16, 2006·The American Journal of Gastroenterology·Moo-In Park, Michael Camilleri
Feb 24, 2001·The American Journal of Gastroenterology·N J TalleyM Horowitz
Jan 19, 2000·The American Journal of Gastroenterology·D L Dumitrascu, M Weinbeck
Nov 14, 2012·The American Journal of Gastroenterology·Michael CamilleriUNKNOWN American College of Gastroenterology

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.